ClinicalTrials.gg
Not yet recruitingNCT07943533HLX22-IITGC-01Updated Nov 17, 2026

HLX22 Combination Therapy in HER2-Positive Limited Metastatic Gastric Cancer

A Phase 2 interventional study of HLX22 and Trastuzumab in HER2-Positive, Limited Metastatic and Gastric Cancer, sponsored by Shanghai Zhongshan Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Shanghai Zhongshan Hospital · Phase 2, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Stomach Neoplasms by Shanghai Zhongshan Hospital — 13 open to participants now, 14 under way, none of them phase 3. Stomach Neoplasms · Shanghai Zhongshan Hospital.

Planned enrollment
16th of 19
30 · median 48
Started
2026
with 1 other
Phase 2
9 of 31
5 open now
Primary completion
2027-12
later than 11 of 13 live
Registered
31st of 31
by date

Among the 31 studies in Stomach Neoplasms by Shanghai Zhongshan Hospital, this one is the 16th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2026, is one of 9 in phase 2, reaches primary completion later than 11 of the 13 other live ones, and was the 31st registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

13 of the 31 studies in Stomach Neoplasms by Shanghai Zhongshan Hospital are open now, in 1 country. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Where they have run

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Stomach Neoplasms by Shanghai Zhongshan Hospital, or all of them as a file.
02

Study summary

This is a prospective, open-label, exploratory study evaluating the efficacy and safety of HLX22 in combination with first-line systemic therapy in patients with HER2-positive, limited metastatic, unresectable gastric or gastroesophageal junction adenocarcinoma. Patients will receive HLX22 combined with trastuzumab and XELOX chemotherapy, with or without the PD-1 inhibitor HLX10 according to PD-L1 and mismatch repair status. The primary endpoint is objective response rate assessed by RECIST v1.1.

Read the detailed description

This study is a prospective, open-label, exploratory clinical trial designed to evaluate the efficacy and safety of HLX22 in combination with first-line systemic therapy in patients with HER2-positive, limited metastatic, unresectable gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Eligible patients will receive HLX22 in combination with trastuzumab and XELOX chemotherapy, with or without the PD-1 inhibitor HLX10 according to PD-L1 combined positive score (CPS) and mismatch repair (MMR) status. The primary endpoint of the study is objective response rate (ORR) assessed according to RECIST version 1.1. Secondary endpoints include disease control rate, conversion surgery rate, pathological response, R0 resection rate, progression-free survival, disease-free survival, overall survival, and safety.

This study aims to explore whether intensification of HER2-targeted therapy combined with chemotherapy, with or without immunotherapy, may improve tumor response and facilitate potential conversion to surgical resection in a selected population of patients with limited metastatic disease.

03

Conditions studied

  • HER2-Positive
  • Limited Metastatic
  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all of the following inclusion criteria:

  1. Voluntarily participate in this clinical study; fully understand and be informed of the study; sign the form (ICF); and be willing and able to comply with and complete all study procedures.
  2. At the time of signing the informed consent form, the subject is a male or female aged ≥18 years.
  3. or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma that has not been previously treated.
  4. Presence of according to version 1.1; target lesions must not consist solely of bone .
  5. -positive tumor, defined as IHC 3+, or IHC 2+ with ISH-positive or FISH-positive.
  6. Limited metastatic disease assessed by a multidisciplinary team (MDT) and deemed unresectable.

    Limited distant metastasis is defined as meeting only a or a single b ± a, as follows:

    a. Abdominal non-regional lymph node metastases, including metastases to the superior mesenteric artery lymph nodes, middle colic artery lymph nodes, para-aortic or retroperitoneal lymph nodes; b1. Limited peritoneal metastasis (P0CY1 or P1a or P1b):P0CY1 is defined as the presence of malignant tumor cells detected by cytological examination of ascites or peritoneal lavage fluid during laparoscopic exploration, without macroscopic visible peritoneal metastatic lesions;P1a is defined as peritoneal metastases limited to areas adjacent to the stomach, greater omentum, lesser omentum, anterior leaf of the transverse mesocolon, pancreatic capsule, and spleen;P1b is defined as peritoneal metastases in the upper abdomen, specifically involving the parietal peritoneum above the umbilicus and the visceral peritoneum above the transverse colon; b2. Liver metastases, with no more than 5 metastatic lesions; b3. Lung metastases, unilateral involvement only, with no more than 5 metastatic lesions; b4. Unilateral or bilateral ovarian metastases; b5. Unilateral or bilateral adrenal gland metastases; b6. Extra-abdominal lymph node metastases confined to a single region, such as cervical lymph nodes, supraclavicular lymph nodes, or mediastinal lymph nodes; b7. Bone metastases confined to a single radiation field; b8. Other limited distant metastases as determined by evaluation of the study team.

  7. No prior antitumor treatment.
  8. (ECOG) performance status score of 0-1.
  9. Expected survival time ≥ 6 months.
  10. surface antigen (HBsAg) negative and hepatitis B core antibody (HBcAb) negative; if HBsAg positive or HBcAb positive, hepatitis B virus DNA (HBV-DNA) must be \< 2500 copies/mL or 500 IU/mL, or within the normal range of the study institution (if the study center has a defined normal range, the HBV-DNA result must fall within that range).
  11. virus (HCV) antibody negative; if HCV antibody positive, HCV-RNA must be negative prior to enrollment. Subjects with concurrent hepatitis B and hepatitis C infection (HBsAg or HBcAb positive and HCV antibody positive) must be excluded.
  12. (HIV) antibody negative.
  13. Adequate organ function, meeting the following criteria (within 14 days prior to randomization, without receiving blood transfusion, albumin, recombinant human thrombopoietin, or colony-stimulating factor [CSF] treatment):

    • Hematologic function (ANC) ≥ 1.5 × 10⁹/L count (PLT) ≥ 100 × 10⁹/L (Hb) ≥ 90 g/L
    • Hepatic function Total (TBIL) ≤ 1.5 × (ULN) (ALT) ≤ 2.5 × ULN; ≤ 5.0 × ULN for patients with liver metastases Aspartate aminotransferase (AST) ≤ 2.5 × ULN; ≤ 5.0 × ULN for patients with liver metastases Alkaline phosphatase (ALP) ≤ 2.5 × ULN; ≤ 5.0 × ULN for patients with liver metastases and/or bone metastases Albumin ≥ 25 g/L
    • Renal function (CrCl) ≥ 50 mL/min (calculated according to the Cockcroft-Gault formula)
    • Coagulation function (APTT) ≤ 1.5 × ULN Prothrombin time (PT) ≤ 1.5 × ULN International normalized ratio (INR) ≤ 1.5 × ULN
  14. Female subjects of must have a negative serum pregnancy test within 7 days prior to randomization. Female subjects of childbearing potential and male subjects with partners of childbearing potential must use at least one highly effective method as defined by the Clinical Trial Facilitation Group (CTFG) during the study treatment period and for at least 9 months after the last study treatment (such as intrauterine devices, oral contraceptives, condoms, female or male sterilization, etc.).

Exclusion criteria

Exclusion Criteria:

Subjects meeting any of the following exclusion criteria will not be eligible for this study:

  1. Subjects with other within the past 2 years. Subjects with cured localized tumors, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, and thyroid cancer may be enrolled.
  2. Prior treatment for locally advanced unresectable or gastric cancer or gastroesophageal junction adenocarcinoma. However, subjects who have received perioperative treatment ( or adjuvant therapy) may be enrolled if there was no disease progression for at least 6 months from completion of treatment to randomization.
  3. Prior use of doxorubicin with a cumulative dose > 360 mg/m² (or equivalent drugs); note: equivalent drugs include epirubicin > 720 mg/m², mitoxantrone > 120 mg/m², idarubicin > 90 mg/m², or cumulative exposure exceeding the equivalent of 360 mg/m² doxorubicin using liposomal doxorubicin or other anthracycline antibiotics. If more than one anthracycline antibiotic was used, the cumulative dose must not exceed the equivalent of 360 mg/m² doxorubicin.
  4. Prior receipt of any -targeted therapy.
  5. Residual toxicity from previous treatments. Alopecia is allowed.
  6. Active gastrointestinal bleeding (grade ≥ 2 according to the National Cancer Institute [NCI] [CTCAE] version 6.0).
  7. Presence of central nervous system (CNS) metastases and/or .
  8. Cerebrovascular accident, myocardial infarction, unstable angina, or uncontrolled arrhythmia (including ≥ 470 ms, calculated using Fridericia's formula) occurring within 6 months prior to randomization.
  9. (NYHA) class III or IV heart failure, or (LVEF) \< 55% as assessed by color Doppler echocardiography (ECHO).
  10. Active infection requiring systemic treatment or active pulmonary tuberculosis; history of interstitial lung disease or complicated interstitial lung disease.
  11. Receipt of within 28 days prior to randomization; seasonal influenza vaccines or inactivated COVID-19 vaccines are excluded from this restriction.
  12. Major surgery within 28 days prior to randomization.
  13. Curative radiotherapy within 28 days prior to randomization.
  14. Participation in another drug study or use of investigational devices within 28 days prior to randomization.
  15. Known severe allergy to any monoclonal antibody or of the investigational drugs.
  16. Known history of psychotropic substance abuse or drug dependence.
  17. Lactating subjects. Subjects who discontinued breastfeeding prior to signing the form and will not breastfeed during the study may be enrolled. Breastfeeding must not be resumed during the study treatment period, and breastfeeding may be resumed 9 months after completion of study treatment.
  18. Known dihydropyrimidine dehydrogenase (DPD) deficiency or current use of antiviral drugs such as sorivudine or chemically related analogs, such as brivudine.
  19. Any previous or current clinical condition, laboratory abnormality, or other situation that, in the investigator's judgment, may interfere with the results of this study or for which participation in this study would not be in the best interest of the subject.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    CPS≥5 and/or dMMR

    Participants with PD-L1 combined positive score (CPS) ≥5 and/or deficient mismatch repair (dMMR) tumors will receive HLX22 in combination with trastuzumab, XELOX chemotherapy, and the PD-1 inhibitor HLX10 as first-line treatment.

    Drug: HLX22 · Drug: Trastuzumab · Drug: XELOX Chemotherapy · Drug: HLX10

  • Experimental
    CPS <5 and pMMR

    Participants with PD-L1 combined positive score (CPS) \<5 and proficient mismatch repair (pMMR) tumors will receive HLX22 in combination with trastuzumab and XELOX chemotherapy as first-line treatment.

    Drug: HLX22 · Drug: Trastuzumab · Drug: XELOX Chemotherapy

Interventions

  • DrugHLX22

    HLX22 is administered intravenously every 3 weeks in combination with standard first-line systemic therapy, according to the protocol.

  • DrugTrastuzumab

    Trastuzumab is administered intravenously in combination with HLX22 and chemotherapy. A loading dose of 8 mg/kg is given at the first administration, followed by maintenance doses of 6 mg/kg every 3 weeks.

  • DrugXELOX Chemotherapy

    XELOX chemotherapy consists of:Oxaliplatin administered intravenously on Day 1 of each 3-week cycle;Capecitabine administered orally twice daily on Days 1-14 of each 3-week cycle.

  • DrugHLX10

    HLX10, a PD-1 inhibitor, is administered intravenously every 3 weeks in participants assigned to the CPS ≥5 or dMMR arm, according to the study protocol.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Objective response rate (ORR) is defined as the proportion of participants achieving a complete response (CR) or partial response (PR), as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: From the start of study treatment to the first tumor response assessment after 4 cycles (each cycle is 21 days; approximately 12 weeks), or up to 6 cycles (approximately 18 weeks) for participants receiving extended treatment.

Secondary outcomes

  1. Disease Control Rate (DCR)

    Disease control rate (DCR) is defined as the proportion of participants achieving complete response (CR), partial response (PR), or stable disease (SD) according to RECIST version 1.1.

    Time frame: From the start of study treatment to the first tumor response assessment after completion of systemic therapy (approximately 12-18 weeks).

  2. Conversion Surgery Rate

    Conversion surgery rate is defined as the proportion of participants who undergo surgical resection with curative intent following systemic therapy, as determined by multidisciplinary team (MDT) assessment.

    Time frame: From the start of study treatment to the time of surgical decision and performance, typically after completion of systemic therapy and prior to disease progression (approximately 12-20 weeks).

  3. Pathological Complete Response (pCR)

    Pathological complete response (pCR) is defined as the absence of residual viable tumor cells in the resected primary tumor and sampled lymph nodes on postoperative pathological examination.

    Time frame: At the time of surgical resection (approximately 12-20 weeks after the start of study treatment), with pCR determined by postoperative pathological examination.

  4. Major Pathological Response (MPR)

    Major pathological response (MPR) is defined as the presence of ≤10% residual viable tumor cells in the resected primary tumor specimen, as determined by postoperative pathological assessment.

    Time frame: At surgical resection, planned 4-6 weeks after completion of 4 or 6 treatment cycles (21 days per cycle), corresponding to approximately 16-18 or 22-24 weeks after treatment initiation, respectively.

  5. Progression-Free Survival (PFS)

    Progression-free survival (PFS) is defined as the time from the date of enrollment to the first documented disease progression according to RECIST v1.1 or death from any cause, whichever occurs first.

    Time frame: From the date of enrollment to the first documented disease progression according to RECIST v1.1 or death from any cause, whichever occurs first, assessed up to 25 months.

  6. Disease-Free Survival

    Disease-free survival (DFS) is defined as the time from the date of surgery to the first documented tumor recurrence, metastasis, or death from any cause, whichever occurs first. DFS will be assessed only in participants who undergo surgery.

    Time frame: From the date of surgery to the first documented tumor recurrence, metastasis, or death from any cause, whichever occurs first, assessed up to approximately 22 months.

  7. Overall Survival

    Overall survival (OS) is defined as the time from the date of enrollment to death from any cause. Participants lost to follow-up will be censored at the date of their last follow-up.

    Time frame: From the date of enrollment to death from any cause, assessed up to 25 months; participants lost to follow-up will be censored at the date of last follow-up.

  8. Adverse Events

    Safety will be assessed by the incidence, severity, and type of adverse events (AEs) and serious adverse events (SAEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 (or version specified in the protocol).

    Time frame: From the first dose of study treatment until 30 days after the last dose of study treatment.

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

Of 295 non-industry phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 76. This study's planned 12 months is below that.

Counting every sponsor, half of 360 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2026
First posted
Nov 17, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07943533
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 17, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion